Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?

Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved..

Severe Acute Respiratory Distress Syndrome caused by a novel human coronavirus SARS-CoV-2 named COVID-19 and declared as a pandemic. This paper reviews the possibility of repurposing angiotensin type 1 receptor (AT1R) antagonists and vitamin D to treat COVID-19. ACE2 protein found on the cell membranes is the target of SARS-CoV-2 for entering into the host cells. Viral spike protein-binding with ACE2 down-regulates it. As ACE2 is known to protect the lung from injuries, SARS-CoV-2-induced ACE2 deficiency may expose patients to lung damage. AT1R antagonists and vitamin D increase the expression of ACE2 independently. Besides, vitamin D suppresses the compensatory increase in renin levels following the inhibition of the renin-angiotensin system by AT1R antagonists. Therefore, a combination of AT1R antagonists and vitamin D may offer protection against COVID-19 induced lung injury.

Media Type:

Electronic Article

Year of Publication:

2020

Contained In:

The American journal of the medical sciences - Vol. 360, No. 4 (2020), p. 338-341

Language:

English

Contributors:

Rafiullah, Mohamed

Links:

Volltext

Keywords:

1406-16-2
Angiotensin II Type 1 Receptor Blockers
Angiotensin converting enzyme 2
Animals
Betacoronavirus
COVID-19
Coronavirus
Coronavirus Infections
EC 3.4.15.1
EC 3.4.17.-
Host-Pathogen Interactions
Humans
Journal Article
Pandemics
Peptidyl-Dipeptidase A
Pneumonia, Viral
Renin-Angiotensin System
Review
SARS
SARS-CoV-2
Severe Acute Respiratory Syndrome
Virus Internalization
Vitamin D
Vitamins

Notes:

Date Completed 09.10.2020

Date Revised 09.10.2020

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1016/j.amjms.2020.07.018

PMID:

32736832

PPN (Catalogue-ID):

NLM314049940